Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1985 Apr;48(1):183–189. doi: 10.1128/iai.48.1.183-189.1985

Serum opsonic activity after immunization of adults with Haemophilus influenzae type b-diphtheria toxoid conjugate vaccine.

K L Cates, K H Marsh, D M Granoff
PMCID: PMC261933  PMID: 3872263

Abstract

We measured the uptake of radiolabeled Haemophilus influenzae type b by human polymorphonuclear leukocytes. Haemophilus influenzae type b strains were preopsonized in individual sera from six adults immunized with type b polysaccharide vaccine (PRP) or six adults immunized with PRP covalently coupled to diphtheria toxoid (PRP-D vaccine). Serum was heat inactivated before use, and exogenous human complement was added. Of the 12 subjects, 3 had high levels of opsonic activity (greater than 40% of immune control) in their preimmunization serum. This activity did not correlate with the concentrations of anti-PRP antibody and was unaffected by absorption of anti-PRP antibody. At 1 month after vaccination, the serum of PRP-D subjects had higher opsonic activity than that from subjects who received PRP (5% serum, mean PRP-D = 86%, mean PRP = 53%, P = 0.001). After 12 months, both groups had higher serum opsonic activity than before immunization (P less than 0.02), but there was no difference between the two groups (mean PRP-D = 48%, mean PRP = 51%). In postimmunization serum, opsonic activity induced by PRP-D or PRP vaccines correlated directly with anti-PRP antibody concentrations as measured by a radioantigen binding assay. We conclude that both vaccines induce opsonic activity, opsonic activity induced by immunization of adults correlates well with the concentration of anti-PRP antibody achieved, and in preimmune sera with low concentrations of anti-PRP antibody, factors other than anti-PRP antibody contribute to opsonic activity.

Full text

PDF

Images in this article

186Image
on p.186

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander H. E., Heidelberger M., Leidy G. The Protective or Curative Element in Type B H. influenzae Rabbit Serum. Yale J Biol Med. 1944 May;16(5):425–434. [PMC free article] [PubMed] [Google Scholar]
  2. Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun. 1983 Jan;39(1):233–238. doi: 10.1128/iai.39.1.233-238.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson P., Johnston R. B., Jr, Smith D. H. Human serum activities against Hemophilus influenzae, type b. J Clin Invest. 1972 Jan;51(1):31–38. doi: 10.1172/JCI106793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bortolussi R., Marrie T. J., Cunningham J., Schiffman G. Serum antibody and opsonic responses after immunization with pneumococcal vaccine in kidney transplant recipients and controls. Infect Immun. 1981 Oct;34(1):20–25. doi: 10.1128/iai.34.1.20-25.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Briles D. E., Claflin J. L., Schroer K., Forman C. Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature. 1981 Nov 5;294(5836):88–90. doi: 10.1038/294088a0. [DOI] [PubMed] [Google Scholar]
  6. Chu C., Schneerson R., Robbins J. B., Rastogi S. C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun. 1983 Apr;40(1):245–256. doi: 10.1128/iai.40.1.245-256.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Feigin R. D., Stechenberg B. W., Chang M. J., Dunkle L. M., Wong M. L., Palkes H., Dodge P. R., Davis H. Prospective evaluation of treatment of Hemophilus influenzae meningitis. J Pediatr. 1976 Apr;88(4 Pt 1):542–548. doi: 10.1016/s0022-3476(76)80002-9. [DOI] [PubMed] [Google Scholar]
  8. Giebink G. S., Foker J. E., Kim Y., Schiffman G. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children. J Infect Dis. 1980 Mar;141(3):404–412. doi: 10.1093/infdis/141.3.404. [DOI] [PubMed] [Google Scholar]
  9. Granoff D. M., Boies E. G., Munson R. S., Jr Immunogenicity of Haemophilus influenzae type b polysaccharide--diphtheria toxoid conjugate vaccine in adults. J Pediatr. 1984 Jul;105(1):22–27. doi: 10.1016/s0022-3476(84)80350-9. [DOI] [PubMed] [Google Scholar]
  10. Granoff D. M., Rockwell R. Experimental Haemophilus influenzae type b meningitis: immunological investigation of the infant rat model. Infect Immun. 1978 Jun;20(3):705–713. doi: 10.1128/iai.20.3.705-713.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Griffin F. M., Jr, Griffin J. A., Leider J. E., Silverstein S. C. Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J Exp Med. 1975 Nov 1;142(5):1263–1282. doi: 10.1084/jem.142.5.1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Johnston R. B., Jr, Anderson P., Rosen F. S., Smith D. H. Characterization of human antibody to polyribophosphate, the capsular antigen of Hemophilus influenzae, type B. Clin Immunol Immunopathol. 1973 Jan;1(2):234–240. doi: 10.1016/0090-1229(73)90024-x. [DOI] [PubMed] [Google Scholar]
  13. Johnston R. B., Jr, Stroud R. M. Complement and host defense against infection. J Pediatr. 1977 Feb;90(2):169–179. doi: 10.1016/s0022-3476(77)80625-2. [DOI] [PubMed] [Google Scholar]
  14. Katz M. A., Solotorovsky M., Lynn M. Opsonization and phagocytosis of Haemophilus influenzae type B organisms by mouse polymorphonuclear leucocytes and antiribosomal serum. Br J Exp Pathol. 1983 Jun;64(3):268–276. [PMC free article] [PubMed] [Google Scholar]
  15. Lepow M. L., Samuelson J. S., Gordon L. K. Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults. J Infect Dis. 1984 Sep;150(3):402–406. doi: 10.1093/infdis/150.3.402. [DOI] [PubMed] [Google Scholar]
  16. Newman S. L., Waldo B., Johnston R. B., Jr Separation of serum bactericidal and opsonizing activities for Haemophilus influenzae type b. Infect Immun. 1973 Sep;8(3):488–490. doi: 10.1128/iai.8.3.488-490.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Peltola H., Käyhty H., Virtanen M., Mäkelä P. H. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med. 1984 Jun 14;310(24):1561–1566. doi: 10.1056/NEJM198406143102404. [DOI] [PubMed] [Google Scholar]
  18. Peterson P. K., Wilkinson B. J., Kim Y., Schmeling D., Quie P. G. Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun. 1978 Mar;19(3):943–949. doi: 10.1128/iai.19.3.943-949.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Santosham M., Moxon E. R. Detection and quantitation of bacteremia in childhood. J Pediatr. 1977 Nov;91(5):719–721. doi: 10.1016/s0022-3476(77)81022-6. [DOI] [PubMed] [Google Scholar]
  20. Schneerson R., Barrera O., Sutton A., Robbins J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med. 1980 Aug 1;152(2):361–376. doi: 10.1084/jem.152.2.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Schneerson R., Robbins J. B., Chu C., Sutton A., Vann W., Vickers J. C., London W. T., Curfman B., Hardegree M. C., Shiloach J. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun. 1984 Sep;45(3):582–591. doi: 10.1128/iai.45.3.582-591.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schneerson R., Rodrigues L. P., Parke J. C., Jr, Robbins J. B. Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b. J Immunol. 1971 Oct;107(4):1081–1089. [PubMed] [Google Scholar]
  23. Shaw S., Smith A. L., Anderson P., Smith D. H. The paradox of Hemophilus infuenzae type B bacteremia in the presence of serum bactericidal activity. J Clin Invest. 1976 Oct;58(4):1019–1029. doi: 10.1172/JCI108525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shenep J. L., Munson R. S., Jr, Barenkamp S. J., Granoff D. M. Further studies of the role of noncapsular antibody in protection against experimental Haemophilus influenzae type b bacteremia. Infect Immun. 1983 Oct;42(1):257–263. doi: 10.1128/iai.42.1.257-263.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stull T. L., Jacobs R. F., Haas J. E., Roberts M. C., Wilson C. B., Smith A. L. Human serum bactericidal activity against Haemophilus influenzae type b. J Gen Microbiol. 1984 Mar;130(3):665–672. doi: 10.1099/00221287-130-3-665. [DOI] [PubMed] [Google Scholar]
  26. Weller P. F., Smith A. L., Anderson P., Smith D. H. The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia. J Infect Dis. 1977 Jan;135(1):34–41. doi: 10.1093/infdis/135.1.34. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES